Celularity Inc. has filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, regaining compliance with Nasdaq's listing requirements after a delay. The company has taken strategic steps including out-licensing its biomaterials portfolio, realigning personnel, and reducing liabilities by about $13 million to strengthen its balance sheet and focus on longevity and cell therapy platforms. This marks a new chapter for Celularity as it aims to build a leaner, more resilient business targeting aging and age-related diseases through regenerative medicine. The company remains committed to operational excellence and long-term value creation for stakeholders.
Near Protocol (NEAR) surged 72% in one week, leading a broader altcoin rally marked by concentrated capital inflows and fragmented liquidity across crypto assets. This rally shows traders favoring assets with sustained momentum rather than short-live...
In 2026, bitcoin price predictions vary widely, with forecasts ranging from a low of $40,000 to a high of $1.5 million. Key figures like Arthur Hayes expect bitcoin to reach $125,000 by year-end, while Michael Saylor projects $1 million by the decade...
Top futures traders are increasing long positions in major altcoins Dogecoin and Ethereum, signaling a rise in short-term risk appetite. Dogecoin's long exposure rose notably in both dollar-margined and coin-margined markets, indicating strong direct...
DeXe (DEXE) surged 22% to $17.65 after breaking above the $16 resistance level that had capped its price since April 2025. Trading volume nearly doubled to $42.5 million, signaling strong market support for the breakout. Technical indicators like the...
Hansa Biopharma announced that its Phase 3 ConfIdeS trial results for kidney transplantation in highly sensitized patients will be presented at the American Transplant Congress on June 22, 2026. The presentation will detail 12-month outcomes, includi...
